What Verdica's 799 score means for ADARE PHARMS INC
Adare Pharms Inc achieves a composite score of 799 out of 850, placing it in the "strong" band (740–799). This score indicates the entity demonstrates solid regulatory compliance across the dimensions Verdica tracks and presents a low-risk profile for business partners or consumers evaluating provider reliability.
A score in this range reflects consistent adherence to state pharmacy board requirements, FDA regulations, and DEA oversight. It does not mean the entity is flawless—the gap between 799 and a perfect 850 suggests room for improvement—but it does signal that Adare has managed its licensing, product approvals, and compliance obligations responsibly. For a business owner or consumer, this score means the provider has passed major regulatory hurdles and maintains active, credible standing with federal and state authorities.
Readers should interpret this score as a marker of institutional stability and regulatory maturity, not as a recommendation or guarantee. It is a starting point for due diligence, not a substitute for it.
How the sub-scores break down
Product Approval (850/850): This perfect sub-score indicates that all products Adare Pharms Inc manufactures or distributes have received required FDA approval or qualification. In the pharmacy industry, this dimension tracks whether drugs are marketed only within their approved indications and whether the company maintains current approvals for each product in its portfolio. A score of 850 means no indexed gaps or deviations in product authorization.
Manufacturer Profile (720/850): This mid-range sub-score suggests the entity meets baseline manufacturer standards but has some documented gaps relative to best practice or regulatory expectations. Manufacturer Profile typically encompasses quality assurance audits, Good Manufacturing Practice (GMP) compliance records, facility inspections, and supply chain documentation. A score of 720 indicates Adare has not faced major facility shutdowns or widespread quality enforcement actions, but state boards or FDA inspectors may have identified minor compliance notes or areas requiring remediation during routine reviews.
FDA Compliance (830/850): This strong sub-score reflects consistent adherence to federal drug regulations and FDA enforcement expectations. FDA Compliance aggregates inspection findings, warning letters, recalls, and adverse event reporting patterns. A score of 830 means Adare Pharms Inc has not triggered significant enforcement concerns and maintains current reporting protocols, though the 20-point gap to a perfect score may reflect minor observations or one-time issues resolved during inspections.
What regulators track for pharmacy providers
State boards of pharmacy maintain licensing records, disciplinary histories, and operational permits for all registered entities. They review complaint logs, continuing education compliance, and adherence to state-specific dispensing or manufacturing rules. A downward movement in board records typically signals license suspensions, operational violations, or unresolved complaints.
The FDA oversees product approval, manufacturing compliance, and quality standards through pre-approval reviews and ongoing facility inspections. Infractions include unapproved product claims, GMP violations, inadequate contamination controls, and failure to report adverse events. Warning letters, import alerts, and recalls all reduce compliance scores.
The DEA tracks controlled substance handling, record-keeping, and diversion prevention for entities holding DEA registrations. Compliance failures include improper storage, missing inventory audits, or suspicious order patterns.
Verdica synthesizes these three data streams to create a composite view. Scores move based on cumulative findings: minor inspection notes lower scores incrementally, while serious violations or license restrictions create steep reductions.
Bottom line
Adare Pharms Inc presents a strong compliance profile with no major red flags in indexed regulatory data. Any party considering a business relationship should still verify current licenses with relevant state boards, request recent FDA inspection reports, and review the specifics of the 30-point gap in Manufacturer Profile to understand whether those findings pose material risk to their use case.